The progress of peptide vaccine clinical trials in gynecologic oncology

Tang, Mi; Cai, Jingye; Diao, Hao-Yang; Guo, Wenmei; Yang, Xiao; Xing, Shasha

doi:10.1080/21645515.2022.2062982

Cited by 11 publications

(6 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the miRNA targeting drugs lacks application in clinical trials. Emerging peptide vaccines aimed to elicit a host immune response against tumor-specific antigens, such as p53, HER2, NY-ESO-1, and FRα, are being evaluated [ 236 ]. However, cancer vaccines have had limited clinical success, and research on most peptide vaccines for gynecological malignancies is still at an exploratory stage.…”

Section: Strategies For Overcoming Drug Resistancementioning

confidence: 99%

Drug resistance in ovarian cancer: from mechanism to clinical trial

Wang,

Zhu

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges for the treatment of drug-resistant ovarian cancer. Continuing to classify drug resistance according to drug type without understanding the underlying mechanisms is unsuitable for current clinical practice. We reviewed the literature regarding various drug resistance mechanisms in ovarian cancer and found that the main resistance mechanisms are as follows: abnormalities in transmembrane transport, alterations in DNA damage repair, dysregulation of cancer-associated signaling pathways, and epigenetic modifications. DNA methylation, histone modifications and noncoding RNA activity, three key classes of epigenetic modifications, constitute pivotal mechanisms of drug resistance. One drug can have multiple resistance mechanisms. Moreover, common chemotherapies and targeted drugs may have cross (overlapping) resistance mechanisms. MicroRNAs (miRNAs) can interfere with and thus regulate the abovementioned pathways. A subclass of miRNAs, “epi-miRNAs”, can modulate epigenetic regulators to impact therapeutic responses. Thus, we also reviewed the regulatory influence of miRNAs on resistance mechanisms. Moreover, we summarized recent phase I/II clinical trials of novel drugs for ovarian cancer based on the abovementioned resistance mechanisms. A multitude of new therapies are under evaluation, and the preliminary results are encouraging. This review provides new insight into the classification of drug resistance mechanisms in ovarian cancer and may facilitate in the successful treatment of resistant ovarian cancer.

show abstract

Section: Strategies For Overcoming Drug Resistancementioning

confidence: 99%

Drug resistance in ovarian cancer: from mechanism to clinical trial

Wang,

Zhu

et al. 2024

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…The peptide vaccines contain peptide epitopes that can overcome the loss or alteration of epitopes during tumor development and increase the opportunity to activate multiple T-cell populations, thus avoiding tumor immune escape. 132 In numerous clinical trials for peptide vaccines using HLA-A2-binding peptides in Europe and the United States, the inclusion criteria required such alleles to be expressed, and approximately one-third of patients met this condition. Peptide sequence selection is the primary condition for peptide vaccines.…”

Section: Immunotherapy Approaches For Tumormentioning

confidence: 99%

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo¹,

Gao²,

Ahmed³

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Protein- and peptide-based cancer vaccines are a form of immunotherapy that stimulate an immune response against TAAs or tumor-specific antigens (TSAs) by utilizing purified, recombinant, or synthetically engineered epitopes and proteins to trigger host immune responses ( 44 , 45 ).…”

Section: Cancer Vaccines Targeting Ny-eso-1mentioning

confidence: 99%

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

Zhou,

Ma,

Liu

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells via major histocompatibility complex class II (MHC-II) and to CD8+ T cells via major histocompatibility complex class I (MHC-I). These mechanisms further enhance the immune response against TAAs mediated by cytotoxic T lymphocytes (CTLs) and helper T cells. NY-ESO-1-based cancer vaccines have a history of nearly two decades, starting from the first clinical trial conducted in 2003. The current cancer vaccines targeting NY-ESO-1 have various types, including Dendritic cells (DC)-based vaccines, peptide vaccines, protein vaccines, viral vaccines, bacterial vaccines, therapeutic whole-tumor cell vaccines, DNA vaccines and mRNA vaccines, which exhibit their respective benefits and obstacles in the development and application. Here, we summarized the current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment, aiming to provide perspectives for future research.

show abstract

The progress of peptide vaccine clinical trials in gynecologic oncology

Cited by 11 publications

References 43 publications

Drug resistance in ovarian cancer: from mechanism to clinical trial

Drug resistance in ovarian cancer: from mechanism to clinical trial

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment

Contact Info

Product

Resources

About